PHENYL-N-QUINOLINE DERIVATIVES FOR TREATMENT OF RNA VIRAL INFECTION Russian patent published in 2023 - IPC C07D215/38 C07D401/12 C07D405/12 A61K31/47 A61K31/4709 A61P31/14 

FIELD: organic chemistry.

SUBSTANCE: invention includes the use of a compound of formula (I) or any of its pharmaceutically acceptable salts for treatment and/or prevention of RNA viral infection, where the RNA viral infection is selected from the RSV (human respiratory syncytial virus) viral infection, Chikungunya virus infection, Dengue virus infection and influenza virus infection, as well as the compounds presented in the claims, their use as a medicine, the use of a pharmaceutical composition based on them and the method for their preparation. In formula (I) of the compound, the use of which is claimed according to claim 1 of the formula of the invention, m is 0 or 1, R³ represents a chlorine atom or a hydrogen atom, R represents a (C₁-C₄)alkyl group or (C₃-C₆)cycloalkyl group, R¹ represents (i) a CF₃ group, (ii) a (C₁-C₁₀)alkyl group, where one of the carbon atoms of said (C₁-C₁₀)alkyl group is optionally replaced by an oxygen atom and said (C₁-C₁₀ )alkyl group is optionally substituted by one of a -CF₃ group, a pyridyl group or a phenyl group, (iii) a (C₃-C₆)cycloalkyl group, or (iv) a phenyl group, or a naphthyl group wherein said groups are optionally substituted with one or two groups independently selected from (C₁-C₄)alkyl group, halogen atom, (C₁-C₅)alkoxy group or -OH group, R² represents (C₁-C₁₀)alkyl group or (C₃-C₆)cycloalkyl group, the OR¹ group is in the para- or meta-phenyl position relative to the -NH- group.

EFFECT: use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for treatment and/or prevention of an RNA viral infection from group IV or V according to the Baltimore classification, selected from the RSV (human respiratory syncytial virus) viral infection, Chikungunya viral infection, dengue virus infection and influenza virus infection.

18 cl, 6 tbl, 8 ex

(I)